SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

被引：20

作者：

Merseburger, Axel S. ^{[2
]}

Apolo, Andrea B. ^{[3
]}

Chowdhury, Simon ^{[4
]}

Hahn, Noah M. ^{[5
]}

Galsky, Matthew D. ^{[6
]}

Milowsky, Matthew I. ^{[7
]}

Petrylak, Daniel ^{[8
]}

Powles, Tom ^{[9
]}

Quinn, David I. ^{[10
]}

Rosenberg, Jonathan E. ^{[11
]}

Siefker-Radtke, Arlene ^{[12
]}

Sonpavde, Guru ^{[13
]}

Sternberg, Cora N. ^{[1
]}

机构：

[1] San Camillo Forlanini Hosp, Dept Med Oncol, Rome, Italy

[2] Univ Hosp Schleswig Holstein, Dept Urol, Campus Lubeck, Lubeck, Germany

[3] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[4] Guys & St Thomas Hosp, London, England

[5] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27515 USA

[8] Yale Canc Ctr, New Haven, CT USA

[9] Barts Canc Inst, London, England

[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[13] Dana Farber Canc Inst, Bladder Canc Ctr, Dept Med Oncol, Boston, MA 02115 USA

来源：

WORLD JOURNAL OF UROLOGY | 2019年 / 37卷 / 01期

关键词：

Bladder cancer; Urothelial cancer; Chemotherapy immunotherapy; Checkpoint inhibitors; TRANSITIONAL-CELL-CARCINOMA; PHASE-II TRIAL; ADVANCED UROTHELIAL CANCER; CISPLATIN-INELIGIBLE PATIENTS; DOSE-DENSE METHOTREXATE; 2ND-LINE TREATMENT; OPEN-LABEL; SINGLE-ARM; 1ST-LINE TREATMENT; WEEKLY PACLITAXEL;

D O I：

10.1007/s00345-018-2486-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The SIU (Societe Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on theaforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

引用

页码：95 / 105

页数：11

共 64 条

[1] Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
Albers, P.
Park, S. -I.
Niegisch, G.
Fechner, G.
Steiner, U.
Lehmann, J.
Heimbach, D.
Heidenreich, A.
Fimmers, R.
Siener, R.
[J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 288 - 294
[2] Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma -: Prognostic factors for response and improvement of quality of life
Albers, P
Siener, R
Härtlein, M
Fallahi, M
Haeutle, D
Perabo, FGE
Steiner, G
Blatter, J
Müller, SC
[J]. ONKOLOGIE, 2002, 25 (01): : 47 - 52
[3] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Apolo, Andrea B.
Infante, Jeffrey R.
Balmanoukian, Ani
Patel, Manish R.
Wang, Ding
Kelly, Karen
Mega, Anthony E.
Britten, Carolyn D.
Ravaud, Alain
Mita, Alain C.
Safran, Howard
Stinchcombe, Thomas E.
Srdanov, Marko
Gelb, Arnold B.
Schlichting, Michael
Chin, Kevin
Gulley, James L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2117 - +
[4] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacqueline
Powles, Thomas
Plimack, Elizabeth R.
Hahn, Noah M.
de Wit, Ronald
Pang, Lei
Savage, Mary J.
Perini, Rodolfo F.
Keefe, Stephen M.
Bajorin, Dean
Bellmunt, Joaquim
[J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
[5] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, Arjun V.
Galsky, Matthew D.
Rosenberg, Jonathan E.
Powles, Thomas
Petrylak, Daniel P.
Bellmunt, Joaquim
Loriot, Yohann
Necchi, Andrea
Hoffman-Censits, Jean
Perez-Gracia, Jose Luis
Dawson, Nancy A.
van der Heijden, Michiel S.
Dreicer, Robert
Srinivas, Sandy
Retz, Margitta M.
Joseph, Richard W.
Drakaki, Alexandra
Vaishampayan, Ulka N.
Sridhar, Srikala S.
Quinn, David I.
Duran, Ignacio
Shaffer, David R.
Eigl, Bernhard J.
Grivas, Petros D.
Yu, Evan Y.
Li, Shi
Kadel, Edward E., III
Boyd, Zachary
Bourgon, Richard
Hegde, Priti S.
Mariathasan, Sanjeev
Thastrom, AnnChristine
Abidoye, Oyewale O.
Fine, Gregg D.
Bajorin, Dean F.
[J]. LANCET, 2017, 389 (10064) : 67 - 76
[6] Southwest oncology group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy
Beer, Tomasz M.
Goldman, Bryan
Nichols, Craig R.
Petrylak, Daniel P.
Agarwal, Manoj
Ryan, Christopher W.
Crawford, E. David
[J]. CLINICAL GENITOURINARY CANCER, 2008, 6 (01) : 36 - 39
[7] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
[8] Bellmunt J., 2018, J Clin Oncol, V36, P410, DOI [DOI 10.1200/JCO.2018.36.6_SUPPL.410, 10.1200/JCO.2018.36.6_suppl.410]
[9] Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Bellmunt, Joaquim
von der Maase, Hans
Mead, Graham M.
Skoneczna, Iwona
De Santis, Maria
Daugaard, Gedske
Boehle, Andreas
Chevreau, Christine
Paz-Ares, Luis
Laufman, Leslie R.
Winquist, Eric
Raghavan, Derek
Marreaud, Sandrine
Collette, Sandra
Sylvester, Richard
de Wit, Ronald
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1107 - 1113
[10] Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Bellmunt, Joaquim
Theodore, Christine
Demkov, Tomasz
Komyakov, Boris
Sengelov, Lisa
Daugaard, Gedske
Caty, Armelle
Carles, Joan
Jagiello-Gruszfeld, Agnieszka
Karyakin, Oleg
Delgado, Francois-Michel
Hurteloup, Patrick
Morsli, Nassim
Salhi, Yacine
Culine, Stephane
von der Maase, Hans
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4454 - 4461

← 1 2 3 4 5 6 7 →